Related Experiment Videos
Alternate chemotherapy in experimental schistosomiasis
M M Ismail1, A M Farghaly, M M Hassan
1Department of Parasitology, Faculty of Medicine, Zagazig University, Egypt.
Journal of the Egyptian Society of Parasitology
|August 1, 1992
Summary
Praziquantel demonstrated higher efficacy than oxamniquine in treating Schistosoma mansoni infections in mice. A second dose, especially of praziquantel, significantly improved cure rates for infections resistant to initial treatment.
Area of Science:
- * Parasitology and Tropical Medicine
- * Pharmacology and Drug Efficacy Studies
Background:
- * Schistosomiasis remains a significant global health concern, necessitating effective treatment strategies.
- * Praziquantel and oxamniquine are key drugs used in schistosomiasis treatment, but their comparative efficacy requires ongoing evaluation.
Purpose of the Study:
- * To compare the efficacy of praziquantel and oxamniquine in treating Schistosoma mansoni infections in a murine model.
- * To assess the effectiveness of a single dose versus a retreatment strategy using the same or an alternative drug.
Main Methods:
- * Murine model of Schistosoma mansoni infection.
- * Oral administration of praziquantel (400 mg/kg) or oxamniquine (100 mg/kg).
- * Monitoring drug efficacy through stool examination and egg counts using the Kato-Katz technique, including single and retreatment regimens.
Main Results:
- * Praziquantel achieved a 60% cure rate after one dose, increasing to 100% after a second dose, outperforming oxamniquine's 37% and 74% cure rates, respectively.
- * Praziquantel led to greater reduction in egg counts in uncured mice compared to oxamniquine.
- * Retreatment with an alternative drug yielded a 100% cure rate with praziquantel and 83% with oxamniquine.
Conclusions:
- * Praziquantel is generally more effective than oxamniquine for treating Schistosoma mansoni infections.
- * A second dose of either praziquantel or oxamniquine, or switching to the alternative drug, can effectively treat cases unresponsive to initial single-dose therapy.